Overview
MEDLIVE (2192)
Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company’s precision marketing and cor...
- Open
- 6.145
- High
- 6.270
- Low
- 6.110
- Prev. Close
- 6.180
- Volume
- 363.00K
- Turnover
- 2.24M
- Avg Price
- 6.164
- Bid/Ask Ratio
- -33.33%
- Amplitude
- 2.59%
- 52wk High
- 14.696
- Volume Ratio
- 0.20
- Turnover Ratio
- 0.05%
- 52wk Low
- 6.000
- HK Mkt Cap
- 4.56B
- Market CapHKD
- 4.56B
- P/ETTM
- 11.62
- P/EDynamic
- 12.25
- P/EStatic
- --
- EPSTTM
- 0.531
- EPSDynamic
- 0.504
- EPSStatic
- --
- BVPS
- 7.48
- P/B
- 0.82
- HK Shares
- 738.34M
- Dividend YieldTTM
- 5.11%
- DividendTTM
- 0.315
- Shares
- 738.34M
- Min lot size
- 500
- Currency
- HKD
MEDLIVE Analyst Rating
View moreForecast & Rating
Sep 23, 2026- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 5
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 6
Medlive opened down as much as 8% at 09:30 to HK$6.080 against the prior close of HK$6.620, then ground higher through the session to HK$6.600 by 13:40 and closed at HK$6.585, down only 0.53% — a low-open, near-full-recovery pattern. The early gap echoed the roughly 9% intraday slide, while daily buybacks running since late October (98,500 shares for HK$613,000 on November 3) absorbed supply; Fidelity's 1.017 million-share add at about HK$6.81 and CITIC Securities' reiterated Buy rating frame the session's HK$6.484 average price. Fundamentals and price position remain in tension: Q2 2026 revenue of HK$182.0 million rose 6.48% year on year, operating income rose 38.5% and net margin held at 51.25%, yet the shares are still down 33.01% year to date, below the MA60 of 6.917 and 56.13% under the 52-week high of 15.01, only 9.75% above yesterday's low of 6.00. Though with just 1.45 million shares traded, the durability of the rebound still needs volume confirmation.
- Nov, 5
Medlive rose 2.70% to HK$6.65, extending a rebound built on buybacks: from 26 October to 3 November the company repurchased about 1.5 million shares for roughly HK$9.49 million, including 98,500 shares on 3 November. The stock spiked to HK$6.795 at 09:44 in the morning session, slid to HK$6.485 at 13:53, then recovered into the close. Q2 2026 revenue was HK$182.0 million, up 6.48% year on year, with net profit of HK$93.29 million (+9.62%), operating income up 38.5% and EPS of HK$0.1262 (+9.78%); Citic Securities reiterated its Buy rating. Even so, the price sits below its 60-day MA of HK$6.94 and is down 32.35% year to date, 55.7% below the 52-week high of HK$15.01 and just 8.66% above the 22 October low of HK$6.12, at 12.53x PE. Though revenue growth remains in single digits and turnover was only 0.18%, buybacks continue to underpin the shares.
- Nov, 3
Medlive slipped 1.67% to HK$6.185, spiking to HK$6.300 in the early session, sliding to HK$6.130 in the afternoon and recovering to HK$6.260 at the close on 1.12 million shares worth HK$6.93 million, thin volume that left buyback support unable to offset moving-average pressure. The company repurchased 1.4015 million shares for about HK$8.88 million over six straight sessions from 26 October to 2 November, including 311,500 shares for HK$1.9616 million on 2 November, while Fidelity added 1.017 million shares at roughly HK$6.81. Interim net profit rose 4% to RMB160 million with a 13.09-cent dividend, against an 11.66x PE and 0.83x PB. The stock is down 37.08% year to date, 58.79% below its 52-week high of HK$15.01 and just 1.06% above the 22 October low of HK$6.12, still under MA20 of 6.434 and MA60 of 6.99, though the buyback remains small against a HK$4.57 billion market cap.
- Oct, 23
Medlive opened at HK$6.12, its intraday low, then climbed through the afternoon session to HK$6.435 at 14:04 BJ before closing at HK$6.420, up 3.55% from the prior close of HK$6.20. The rebound off yesterday's HK$6.12 52-week low was supported by Citic Securities reaffirming its Buy rating, Fidelity adding 1.017 million shares at about HK$6.81, and an interim net profit up 4% to RMB160 million alongside a 13.09-cent dividend. Still, fundamentals sit uneasily against the price: Q2 revenue of HK$182 million rose 6.48% yoy, net profit 9.62% and operating income 38.5%, with PE at 12.1x and PB 0.86x, while the stock is down 34.69% year-to-date, 57.23% below its January 12 52-week high of HK$15.01, and below its MA20 of HK$6.553.
- Oct, 22
Medlive fell 3.58% to HK$6.200 from the prior close of HK$6.430, tracing a high-open-then-drift-lower pattern in which the day high of HK$6.430 was set at the open and the low of HK$6.160 arrived at 15:40 in the Hong Kong afternoon session. Citic Securities reaffirmed its Buy rating and Fidelity added 1.017 million shares at roughly HK$6.81, yet neither stopped the slide. Interim net profit rose 4% to RMB160 million alongside a 13.09-cent dividend, while 96.137 million shares were released from pledge and re-pledged for a RMB300 million loan. Q2 2026 net profit grew 9.62% yoy, operating income 38.5% and net margin held at 51.25%, but the price sits below MA20 of 6.58 and MA60 of 7.18, down 36.93% year-to-date, 58.69% below the 52-week high of 15.01 and just 0.8% above the 52-week low of 6.15, with PE at 11.71 and PB at 0.83. Though the auditor switch from EY to Deloitte remains an overhang on governance perception.
News
PUBT · Medlive Technology Files Next-Day Disclosure Return With HKEX Announcing Share Buyback
PUBT · Medlive Technology files next day disclosure return with HKEX announcing share repurchase
PUBT · Medlive Technology Files Next Day Disclosure Return to HKEX Announcing Share Buyback
PUBT · Medlive Technology discloses share buyback in HKEX next-day return
Market Movers · Medlive drops 9% in Hong Kong trading
Market Movers · Medlive climbs nearly 5%
